Alimera Sciences Inc

Alimera Sciences — Q4 2015 Earnings Presentation

15 slides from Alimera Sciences's earnings presentation, Mar 3, 2016

  1. Slide 1: Exhibit 99.2

    Exhibit 99.2 1

  2. Slide 2: Results Conference Call Fourth Quarter 2015

    Results Conference Call Fourth Quarter 2015

  3. Slide 3: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the ability of the ILUVIEN J-code to drive use and market acceptance of ILUVIEN, the opportunity for further

  4. Slide 4: 2015 Accomplishments

    4 ILUVIEN® Launched in US 2015 Accomplishments 167% Annual Revenue Growth ILUVIEN® Launched in Portugal, ILUVIEN® Re-launch in Germany 167% 2015 Revenue Growth

  5. Slide 5: Full Year and Fourth Quarter Revenue

    5 Full Year Revenue $22.4M 2015 2014 $8.4M US Sales EU Sales Fourth Quarter Revenue $5.8M 4Q15 4Q14 $1.7M 99% EU 33.2% EU 66.8% US 99.8% EU 0.2% US 32.4% EU 67.6% US Sales Growth $15.2M 2015 US Revenue $7.3M 2015 EU Revenue 1.0% US

  6. Slide 6: 4Q15 Highlights

    6 J-Code Approval in US (Active 1/1/16) US User Base Grew to 312 Accounts 4Q15 Highlights 241% Year-Over-Year Fourth Quarter Growth German Unit Demand Equivalent to Highest Previous Quarter Licensing Agreement Completed in Middle East 241% Q415 Revenue Growth

  7. Slide 7: United States: J-Code and Benefit Investigations

    7 J-Code Loaded in Majority of Systems Benefit Investigations Strong in Q1 2016 United States

  8. Slide 8: United States Sales Executives and Accounts at Year-end

    United States 8 37 Sales Executives 312 Accounts at Year-end

  9. Slide 9: Europe: Germany Volume Up 63%

    9 Europe Germany Volume up 63% in Q4 2015 Versus Q4 2014 Reimbursement Coverage Continues to Grow

  10. Slide 10: Europe: Portugal Record Sales, UK Slowdown

    10 Portugal finished 2015 with record quarterly sales Slowdown in UK sales continues due to NICE endorsement Measures in place; moving toward growth again Europe Slowdown in UK Sales Continues Due to NICE Endorsement of Competitor Products Portugal Finished 2015 With Record Quarterly Sales

  11. Slide 11: Financial Overview

    Financial Overview Rick Eiswirth

  12. Slide 12: Select Income Statement Data

    12 (000’s) Three Months Ended December 31 2015 Three Months Ended December 31 2014 12 Months Ended December 31 2015 12 Months Ended December 31 2014 Revenue $5,823 $1,741 $22,438 $8,423 Gross Profit $5,354 $1,611 $20,767 $6,981 Gross Margin 92% 93% 93% 83% Net Loss from Operations ($9,761) ($10,920)

  13. Slide 13: Closing Remarks

    Closing Remarks Dan Myers ALIME SCIENCES

  14. Slide 14: Summary

    14 Summary Initiated Commercial Operations in US EU Progressing Well, Will be Leveraging Real- World Data Middle East Expansion/International Expansion

  15. Slide 15: Question & Answer Session

    Question & Answer Session ALIME SCIENCES

Alimera Sciences — Q4 2015 Earnings Presentation on 6ix